诱导多能干细胞
生物
嵌合抗原受体
CD19
细胞生物学
克隆(Java方法)
抗原
T细胞
免疫学
免疫系统
胚胎干细胞
遗传学
基因
作者
Zhiqiang Wang,Helen P. McWilliams-Koeppen,Hernan Reza,Julie R. Ostberg,Wuyang Chen,Xiuli Wang,Christian Huynh,Vibhuti Vyas,Wen-Chung Chang,Renate Starr,Jamie R. Wagner,Brenda Aguilar,Xin Yang,Xiwei Wu,Jinhui Wang,Wei Chen,Ellery Koelker-Wolfe,Christopher S. Seet,Amélie Montel‐Hagen,Gay M. Crooks,Stephen J. Forman,Christine E. Brown
出处
期刊:Cell Stem Cell
[Elsevier]
日期:2022-03-11
卷期号:29 (4): 515-527.e8
被引量:76
标识
DOI:10.1016/j.stem.2022.02.009
摘要
Unlimited generation of chimeric antigen receptor (CAR) T cells from human-induced pluripotent stem cells (iPSCs) is an attractive approach for "off-the-shelf" CAR T cell immunotherapy. Approaches to efficiently differentiate iPSCs into canonical αβ T cell lineages, while maintaining CAR expression and functionality, however, have been challenging. We report that iPSCs reprogramed from CD62L+ naive and memory T cells followed by CD19-CAR engineering and 3D-organoid system differentiation confers products with conventional CD8αβ-positive CAR T cell characteristics. Expanded iPSC CD19-CAR T cells showed comparable antigen-specific activation, degranulation, cytotoxicity, and cytokine secretion compared with conventional CD19-CAR T cells and maintained homogeneous expression of the TCR derived from the initial clone. iPSC CD19-CAR T cells also mediated potent antitumor activity in vivo, prolonging survival of mice with CD19+ human tumor xenografts. Our study establishes feasible methodologies to generate highly functional CAR T cells from iPSCs to support the development of "off-the-shelf" manufacturing strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI